false 0000876378 0000876378 2022-06-14 2022-06-14
 


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_________________
 
FORM 8-K
_________________
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
June 14, 2022
Date of Report (date of earliest event reported)
_________________
 
Asensus Surgical, Inc.
(Exact name of Registrant as specified in its charter)
_________________
 
Delaware   0-19437   11-2962080
(State or other jurisdiction of incorporation or organization)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification Number)
 
1 TW Alexander Drive, Suite 160
Durham, NC 27703
(Address of principal executive offices)
 
919-765-8400
(Registrants telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
_________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading symbol
 
Name of each exchange on which registered
Common Stock
$0.001 par value per share
 
ASXC
 
NYSE American
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 


 
 

 
Item 5.07
Submission of Matters to a Vote of Security Holders.
 
On June 14, 2022, Asensus Surgical, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the total number of shares represented in person or by proxy was 111,427,690.75 of the 236,415,789 shares of Common Stock outstanding and entitled to vote at the Annual Meeting as of the record date, April 18, 2022. The following matters were voted upon at the Annual Meeting:
 
1.    Election of Directors. The following named persons were elected as Directors of the Company to serve until the next Annual Meeting of Stockholders in 2023 or until their successors are elected and qualified. The votes cast were as follows:
 
Director Nominee     For       Vote Withheld  
                 
David B. Milne
    37,965,825.90       13,271,415.95  
Anthony Fernando
    41,427,918.77       9,809,322.08  
Andrea Biffi
    43,152,531.64       8,084,709.21  
Kevin Hobert
    48,001,657.21       3,235,584.64  
Elizabeth Kwo
    47,964,808.81       3,272,432.03  
Richard C. Pfenniger, Jr.
    38,251,791.83       12,985,449.02  
William N. Starling
    40,201,628.69       11,035,613.16  
 
There were 60,190,448.89 broker non-votes for this proposal.
 
2.    Say on Pay. The stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers for 2021, as described in the proxy statement for the Annual Meeting in accordance with Regulation S-K, Item 402. The stockholder vote was as follows:
 
 
            27,882,377.59 Votes
 
FOR the resolution
 
 
                    22,296,247.89 Votes
 
AGAINST the resolution
 
 
 1,058,615.36 Votes
 
ABSTAIN
 
 
There were 60,190,449.89 broker non-votes for this proposal.
 
3.    Ratification of Independent Public Accounting Firm for 2022. The stockholders voted to ratify the appointment of BDO USA, LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2022. The stockholder vote was as follows:
 
 
108,294,852.77 Votes
 
FOR the resolution
 
 
2,068,290.47 Votes
 
AGAINST the resolution
 
 
  1,064,547.49 Votes
 
ABSTAIN
 
 
There were no broker non-votes for this proposal.
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  ASENSUS SURGICAL, INC.
   
Date: June 14, 2022 /s/ Shameze Rampertab
  Shameze Rampertab
  Executive Vice President and Chief Financial Office
 
2
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Déc 2022 à Jan 2023 Plus de graphiques de la Bourse Asensus Surgical
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Jan 2022 à Jan 2023 Plus de graphiques de la Bourse Asensus Surgical